Robert W. Baird analyst Brian Skorney maintained a Hold rating on Gilead Sciences (GILD - Research Report) on September 12 and set a price target of $63.00. The company's shares closed yesterday at $65.10.Skorney covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Amgen, and Biogen. According to TipRanks, Skorney has an average return of -4.1% and a 46.42% success rate on recommended stocks. In addition to Robert W. Baird, Gilead Sciences also received a Hold from Piper Sandler's Do Kim in a report issued on September 12. However, on the same day, Mizuho Securities maintained a Buy rating on Gilead Sciences (NASDAQ: GILD).
https://www.tipranks.com/news/blurbs/robert-w-baird-keeps-their-hold-rating-on-gilead-sciences-gild?utm_source=advfn.com&utm_medium=referral